Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naoxueshu Oral Liquid for Chronic Subdural Hematoma
ChiCTR2400090565Phase 4Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of naoxueshu in Chronic subdural haematoma (CSDH), sponsored by Beijing Tiantan Hospital. Primary endpoint: Hematoma volume. Started Oct 2024; status: completed.
02
Drugs
naoxueshu
03
Conditions
Chronic subdural haematoma (CSDH)
Beyond the preview
Go deeper on ChiCTR2400090565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090565.